OTCPK:IMLE

Stock Analysis Report

Executive Summary

TransBiotec, Inc. develops non-invasive alcohol sensing systems.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has TransBiotec's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMLE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-18.8%

IMLE

-0.1%

US Electronic

0.06%

US Market


1 Year Return

712.5%

IMLE

8.5%

US Electronic

19.3%

US Market

Return vs Industry: IMLE exceeded the US Electronic industry which returned 8.5% over the past year.

Return vs Market: IMLE exceeded the US Market which returned 19.3% over the past year.


Shareholder returns

IMLEIndustryMarket
7 Day-18.8%-0.1%0.06%
30 Day-18.8%-3.8%1.7%
90 Day72.0%3.0%9.0%
1 Year712.5%712.5%9.6%8.5%21.8%19.3%
3 Year150.0%150.0%37.4%33.7%49.5%39.9%
5 Year1525.0%1525.0%70.5%62.2%73.1%54.1%

Price Volatility Vs. Market

How volatile is TransBiotec's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is TransBiotec undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether TransBiotec is trading at an attractive price based on the cash flow it is expected to produce in the future. But as TransBiotec has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of IMLE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through TransBiotec regulatory filings here.
  • Explore potentially undervalued companies in the Tech industry.

Future Growth

How is TransBiotec forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.7%

Forecasted Tech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TransBiotec has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of IMLE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access TransBiotec's filings and announcements here.
  • Explore growth companies in the Tech industry.

Past Performance

How has TransBiotec performed over the past 5 years?

0.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMLE is currently unprofitable.

Growing Profit Margin: IMLE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMLE is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.

Accelerating Growth: Unable to compare IMLE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMLE is unprofitable, making it difficult to compare its past year earnings growth to the Electronic industry (14.6%).


Return on Equity

High ROE: IMLE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is TransBiotec's financial position?


Financial Position Analysis

Short Term Liabilities: IMLE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IMLE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IMLE has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: IMLE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: IMLE has a low level of unsold assets or inventory.

Debt Coverage by Assets: IMLE has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMLE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IMLE has less than a year of cash runway if free cash flow continues to grow at historical rates of 21.2% each year.


Next Steps

Dividend

What is TransBiotec's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IMLE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IMLE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMLE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMLE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMLE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Kevin Moore 0

0.3yrs

Tenure

0

Mr. Kevin Moore serves as Chief Executive Officer at TransBiotec, Inc. since October 25, 2019 and Director since December 2, 2019. From 2017 to 2019, Mr. Moore was the President of Moore Holdings, Inc. and ...


Leadership Team

NamePositionTenureCompensationOwnership
Charles Bennington
President13.2yrsUS$69.00k6.28% $487.6k
Nick Noceti
Interim Chief Financial Officer1.7yrsUS$73.50k0.33% $25.5k
Kevin Moore
CEO & Director0.3yrsno data1% $78.0k
Michael Lanphere
Vice President of Legal Affairs & General Counsel3yrsno data29.96% $2.3m
David Gandini
Chief Revenue Officer & Director0.2yrsno datano data

1.7yrs

Average Tenure

59yo

Average Age

Experienced Management: IMLE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Charles Bennington
President13.2yrsUS$69.00k6.28% $487.6k
Kevin Moore
CEO & Director0.3yrsno data1% $78.0k
David Gandini
Chief Revenue Officer & Director0.2yrsno datano data
Gary Graham
Director0.3yrsno datano data

0.2yrs

Average Tenure

Experienced Board: IMLE's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.5%.


Top Shareholders

Company Information

TransBiotec, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TransBiotec, Inc.
  • Ticker: IMLE
  • Exchange: OTCPK
  • Founded: 2004
  • Industry: Electronic Equipment and Instruments
  • Sector: Tech
  • Market Cap: US$7.762m
  • Shares outstanding: 238.83m
  • Website: https://www.transbiotec.com

Location

  • TransBiotec, Inc.
  • 400 North Tustin Avenue
  • Suite 225
  • Santa Ana
  • California
  • 92705
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMLEOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2011

Biography

TransBiotec, Inc. develops non-invasive alcohol sensing systems. It develops SOBR, a transdermal sensing system that detects blood alcohol levels through a person's skin. The company was founded in 2004 and is based in Santa Ana, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/21 01:12
End of Day Share Price2020/02/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.